Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

220

Participants

Timeline

Start Date

January 17, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

November 30, 2027

Conditions

Advanced Non-small Cell Lung Cancer

Interventions

DRUG

JSKN016

Administered intravenously according to protocol.

DRUG

Docetaxel

Administered intravenously according to protocol.

All Listed Sponsors

lead

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

INDUSTRY